Macrophage membrane-encapsulated liposomes of protopanaxadiol-type doxorubicin hydrochloride improve formulation stability for the treatment of triple-negative breast cancer

Key Points

• This research aims to investigate how macrophage membrane-encapsulated liposomes can stabilize doxorubicin for treating triple-negative breast cancer.
• Conducted in vitro experiments to assess formulation stability.
• Performed in vivo studies to evaluate antitumor effects.
• Used doxorubicin hydrochloride encapsulated in liposomes combined with protopanaxadiol.
• Found that DOX-(PPD)-LIP@M significantly improves the stability of the drug formulation.
• Observed an enhanced antitumor effect compared to standard doxorubicin treatment.